Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cendakimab in Eosinophilic Gastroenteritis
NCT05214768Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of cendakimab in eosinophilic gastroenteritis (EGE), sponsored by Celgene Corporation. Started Mar 2022; status: completed.
02
Drugs
cendakimab
03
Conditions
eosinophilic gastroenteritis (EGE)
Beyond the preview
Go deeper on NCT05214768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214768.